



**ASX & Media Release**

## **European Patent Granted for Pre-clinical IgM Candidate PAT-LM1**

**Melbourne, Australia; 1 August, 2018:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company is pleased to advise that it has been granted a European patent for its anti-cancer pre-clinical candidate PAT-LM1.

The European Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family; patent number 2390269; entitled "Neoplasm specific antibodies and uses thereof".

The European patent is derived from one of a series of patent applications that have been submitted to cover the PAT-LM1 antibody. The claims in this patent cover the antibody *per se* as well as its use in treating and diagnosing cancer.

To date, 14 patents across three PAT-LM1 families have been granted in jurisdictions including the United States and Europe. This is the last patent to grant in the PAT-LM1 portfolio.

"Patrys has an ongoing program to out-license PAT-LM1 and the granting of this final patent strengthens the intellectual property portfolio for business development efforts around our IgM platform," said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys.

**-Ends-**

**For further information, please contact:**

Patrys Limited:  
James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:  
Ben Walsh  
WE Buchan  
P: +61 2 9237 2801  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).